Studies have shown that IDH mutations are not only a disease-defining biomarker and oncogenic driver in glioma, but are also a neoantigen and modulator of glioma immune evasion and are associated with an immunosuppressive phenotype (12, 13). This evidence concerns the gene IDH2 and glioma.